- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nausea and Vomiting
- Interventions
- Cesamet
- Drug
- Lead sponsor
- Veeda Oncology
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Whittier, California • Grand Junction, Colorado + 8 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Auricular percutaneous neurostimulation, Sham percutaneous neurostimulation
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
- Interventions
- GW679769, Dexamethasone, Ondansetron Hydrochloride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Fosaprepitant
- Drug
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Olanzapine 5 MG, Placebo
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 28
- States / cities
- Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Intranasal granisetron
- Drug
- Lead sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- The Study Is Managed by Kendle International, in Wilmington, North Carolina
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- granisetron transdermal system, Granisetron IV
- Drug
- Lead sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Nausea With Vomiting Chemotherapy-Induced
- Interventions
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Drug
- Lead sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Anaheim, California • Ocala, Florida • Skokie, Illinois + 4 more
- Conditions
- Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- Real Acupressure Band, Placebo Acupressure Band
- Procedure
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 24
- States / cities
- Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Oral palonosetron, I.V. palonosetron, Dexamethasone
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 6 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- Netupitant, Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- Olanzapine, Aprepitant
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Ovarian Cancer, Uterine Cancer
- Interventions
- fosaprepitant, aprepitant, Oral Placebo, IV placebo
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Associates
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- APF530, dexamethasone, Palonosetron Hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 52
- States / cities
- Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more
- Conditions
- Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
- Drug · Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
- Interventions
- Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Robbinsdale, Minnesota
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ginger extract, placebo
- Drug · Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 5
- States / cities
- South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more